Cryopreservation liquid for tissues and preparation method thereof

Through a new frozen solution formula, the DMSO and serum in traditional frozen solution are abandoned, and culture medium, buffer, cryoprotectants, antioxidants and serum substitutes are used to solve the poor cell viability in traditional frozen solution. and the issue of contamination risk has achieved safe and efficient long-term preservation of skin tissue.

CN119032932APending Publication Date: 2024-11-29QIZAI BIOTECHNOLOGY (CHENGDU) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411144458.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Traditional frozen liquids often contain DMSO and serum, resulting in poor cell viability, risk of cell damage and pathogen contamination, and it is difficult to meet the long-term preservation needs of skin tissue.

Method used

Using a new frozen solution formula, including medium, buffer, cryoprotective agent, antioxidants, serum substitutes and antibiotics, DMSO and serum are abandoned, and microbial contamination is ensured through a combination of specific proportions and filtration.

Benefits of technology

It achieves long-term and stable skin tissue preservation without damaging tissue activity, avoiding batch differences and contamination risks in cell damage and serum use, and providing a safe and efficient freezing effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119032932A_ABST
    Figure CN119032932A_ABST
Patent Text Reader

Abstract

The invention discloses a cryopreservation solution for tissues and a preparation method of the cryopreservation solution. The cryopreservation solution comprises a culture medium solution, a buffer solution, a cryoprotectant, an antioxidant, a serum substitute and antibiotics, the culture medium liquid comprises a glucose and amino acid mixture; the buffer solution comprises sodium chloride, potassium chloride, anhydrous disodium hydrogen phosphate, sodium dihydrogen phosphate monohydrate, zinc sulfate heptahydrate, sodium bicarbonate and sodium hydroxide; the cryoprotectant comprises propylene glycol, cane sugar and trehalose; the serum substitute comprises D-biotin, choline chloride, folic acid, inositol, nicotinamide, D-calcium pantothenate, pyridoxal hydrochloride, pyridoxine hydrochloride, riboflavin, ammonium sulfate hydrochloride and hypoxanthine; the antibiotics comprise gentamicin; the specific preparation method comprises the following steps: step 1, preparing a buffer solution; and step 2, preparing the cryopreservation liquid. According to the invention, DMSO and serum components commonly used in a traditional cryopreservation solution are abandoned, and long-term stable preservation of tissues can be realized on the premise of not damaging tissue activity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of cryopreservation fluid, and in particular to a cryopreservation fluid for tissues and a preparation method thereof. Background Art

[0002] After the cell culture reaches the required amount or target, the cultured cells need to be collected and preserved. However, room temperature and 4°C are not enough to preserve cells for a long time, so the cells need to be cryopreserved at ultra-low temperatures, which involves the use of cryopreservation fluid.

[0003] At present, conventional cryopreservation fluids are composed of serum, animal-derived proteins, or common chemical reagents that do not meet the requirements for clinical use. On the one hand, such cryopreservation fluids have poor effects on maintaining cell viability or potency. On the other hand, since their components cannot be unified, they are difficult to meet the standards for clinical use.

[0004] More importantly, in the study of skin tissue preservation, traditional cryopreservation fluids often contain ingredients such as DMSO and serum. However, DMSO is cytotoxic and may cause damage to skin tissues if used for a long time; and serum sources are limited, with batch differences and potential risks of pathogen contamination. Therefore, developing a DMSO-free and serum-free cryopreservation fluid is of great significance for the long-term preservation of tissues. Summary of the invention

[0005] The purpose of the present invention is to provide a freezing solution for tissue and a preparation method thereof. The present invention abandons the DMSO and serum components commonly used in traditional freezing solutions and is a new, safe and efficient skin tissue freezing solution that can achieve long-term stable preservation without damaging tissue activity.

[0006] In order to solve the above technical problems, the technical solution adopted by the present invention is:

[0007] A method for preparing a freezing solution for tissues, wherein the freezing solution comprises a culture medium, a buffer, a cryoprotectant, an antioxidant, a serum substitute and an antibiotic;

[0008] Wherein, the culture medium comprises a mixture of glucose and amino acids;

[0009] Buffers include sodium chloride, potassium chloride, disodium hydrogen phosphate anhydrous, sodium dihydrogen phosphate monohydrate, zinc sulfate heptahydrate, sodium bicarbonate, and sodium hydroxide;

[0010] Cryoprotectants include propylene glycol, sucrose, and trehalose;

[0011] Serum substitutes include D-biotin, choline chloride, folic acid, inositol, niacinamide, D-calcium pantothenate, pyridoxal hydrochloride, pyridoxine hydrochloride, riboflavin, ammonium sulfate hydrochloride, and hypoxanthine;

[0012] Antibiotics include gentamicin;

[0013] The specific preparation method is as follows:

[0014] Step 1, buffer preparation:

[0015] Put 6-9g of sodium chloride, equal weights of potassium chloride, anhydrous disodium hydrogen phosphate, monohydrated sodium dihydrogen phosphate, heptahydrated zinc sulfate, sodium bicarbonate and sodium hydroxide (totaling 2-4g) into a clean beaker, add about 700-800ml of distilled water into the container, stir to completely dissolve the solid, adjust the pH to 7.0-7.4 with sodium hydroxide, continue to add distilled water until the total volume reaches 1L, stir again to make a buffer solution for use;

[0016] Step 2, preparation of cryopreservation solution:

[0017] Mix 25-35g of glucose, 8-12g of amino acid mixture, 1.7-2.3g of antioxidant, 4-6g of serum substitute, and 0.8-1.2g of gentamicin evenly into a clean beaker, add buffer to 800-900ml, and stir evenly, then add cryoprotectant and continue stirring evenly;

[0018] The prepared buffer and freezing solution were filtered through a sterile filter using a 0.22 um filter membrane to ensure that there was no microbial contamination.

[0019] Further, in some preferred embodiments, the amino acid mixture includes 1-2 parts of L-alanine, 2-4 parts of L-alanine-L-glutamine, 3-5 parts of L-isoleucine, 1-6 parts of L-methionine, 3-6 parts of L-phenylalanine, 4-8 parts of L-proline, 5-7 parts of L-serine, 9-10 parts of L-threonine and 5-8 parts of L-tryptophan.

[0020] Further, in some preferred embodiments, the amino acid mixture includes 1.5 parts of L-alanine, 3 parts of L-alanine-L-glutamine, 4 parts of L-isoleucine, 3 parts of L-methionine, 4 parts of L-phenylalanine, 6 parts of L-proline, 6 parts of L-serine, 9 parts of L-threonine and 3 parts of L-tryptophan.

[0021] Furthermore, in some preferred implementation cases, the antioxidant includes 0.9-1.1 g of sodium L-ascorbate, 0.4-0.6 g of vitamin E, and 0.4-0.6 g of vitamin C.

[0022] Furthermore, in some preferred implementation cases, the antioxidant includes 1 g of sodium L-ascorbate, 0.5 g of vitamin E, and 0.5 g of vitamin C.

[0023] Furthermore, in some preferred implementation cases, the cryoprotectant contains 90-110 ml of propylene glycol, 0.8-1.2 g of sucrose, and 0.8-1.2 g of trehalose.

[0024] Furthermore, in some preferred implementation cases, the cryoprotectant contains 100 ml of propylene glycol, 1 g of sucrose, and 1 g of trehalose.

[0025] Further, in some preferred embodiments, the serum substitute includes 2-3 parts of D-biotin, 2-5 parts of choline chloride, 5-6 parts of folic acid, 3-6 parts of inositol, 2-4 parts of nicotinamide, 5-6 parts of D-calcium pantothenate, 1-2 parts of pyridoxal hydrochloride, 1-3 parts of pyridoxine hydrochloride, 1-2 parts of riboflavin, 2-3 parts of ammonium sulfate hydrochloride and 1-2 parts of hypoxanthine.

[0026] In addition, the present invention also discloses a cryopreservation solution, which is prepared by the above-mentioned method for preparing the cryopreservation solution for tissues.

[0027] Compared with the prior art, the present invention has the following beneficial effects:

[0028] The present invention mainly consists of culture medium, buffer, cryoprotectant, antioxidant, serum substitute and antibiotic. The cryopreservation solution of the present invention abandons the DMSO and serum components commonly used in traditional cryopreservation solutions, and is a novel, safe and efficient skin tissue cryopreservation solution that can achieve long-term stable storage without damaging tissue activity. It can avoid damage to skin tissue during use, reduce the use of serum, and avoid batch differences and potential pathogen contamination risks. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments will be briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without paying creative work.

[0030] Figure 1 This is a flow cytometry chart of the viability of fresh tissue cells of the present invention.

[0031] Figure 2 This is a flow cytometry analysis of tissue cell survival rate after cryopreservation in Wako cryopreservation medium.

[0032] Figure 3 This is a flow cytometry graph of the survival rate of tissue cells after being cryopreserved in the cryopreservation solution of the present invention.

[0033] Figure 4 This is a flow cytometry graph showing the survival rate of tissue cells after being cryopreserved in Yazyme cryopreservation solution.

[0034] Figure 5 This is a flow cytometry analysis of tissue cell survival rate after cryopreservation in Xiaopeng cryopreservation fluid.

[0035] Figure 6 This is a flow cytometry chart of tissue cell survival rate after cryopreservation with Azes cryopreservation solution.

[0036] Figure 7 The present invention uses flow cytometry to examine the cell apoptosis survival rate. DETAILED DESCRIPTION

[0037] In the following, only some exemplary embodiments are briefly described. As those skilled in the art will appreciate, the described embodiments may be modified in various ways without departing from the spirit or scope of the embodiments of the present invention. Therefore, the drawings and descriptions are considered to be exemplary and non-restrictive in nature. Embodiments of the present invention are described in detail below in conjunction with the accompanying drawings.

[0038] Embodiment 1

[0039] This embodiment discloses a method for preparing a freezing solution for tissues, wherein the freezing solution includes a culture medium, a buffer, a cryoprotectant, an antioxidant, a serum substitute, and an antibiotic;

[0040] Wherein, the culture medium comprises a mixture of glucose and amino acids;

[0041] Buffers include sodium chloride, potassium chloride, disodium hydrogen phosphate anhydrous, sodium dihydrogen phosphate monohydrate, zinc sulfate heptahydrate, sodium bicarbonate, and sodium hydroxide;

[0042] Cryoprotectants include propylene glycol, sucrose, and trehalose;

[0043] Serum substitutes include D-biotin, choline chloride, folic acid, inositol, niacinamide, D-calcium pantothenate, pyridoxal hydrochloride, pyridoxine hydrochloride, riboflavin, ammonium sulfate hydrochloride, and hypoxanthine;

[0044] Antibiotics include gentamicin;

[0045] The specific preparation method is as follows:

[0046] Step 1, buffer preparation:

[0047] Put 6-9g of sodium chloride, equal weights of potassium chloride, anhydrous disodium hydrogen phosphate, monohydrated sodium dihydrogen phosphate, heptahydrated zinc sulfate, sodium bicarbonate and sodium hydroxide (totaling 2-4g) into a clean beaker, add about 800ml of distilled water into the container, stir to completely dissolve the solid, adjust the pH to 7.0-7.4 with sodium hydroxide, continue to add distilled water until the total volume reaches 1L, stir again to make a buffer solution for use;

[0048] In this embodiment, 7 g of sodium chloride, 3 g of potassium chloride, anhydrous disodium hydrogen phosphate, sodium dihydrogen phosphate monohydrate, zinc sulfate heptahydrate, sodium bicarbonate and sodium hydroxide are used in total.

[0049] Step 2, preparation of cryopreservation solution:

[0050] Mix 25-35g of glucose, 8-12g of amino acid mixture, 1.7-2.3g of antioxidant, 4-6g of serum substitute, and 0.8-1.2g of gentamicin evenly into a clean beaker, add buffer to 800-900ml, and stir evenly, then add cryoprotectant and continue stirring evenly;

[0051] Among them, in this embodiment, glucose is about 30g, amino acid mixture is 10g, antioxidant is 2g, serum substitute is 5g, and gentamicin is 1g.

[0052] The antioxidant includes 0.9-1.1 g of sodium L ascorbate, 0.4-0.6 g of vitamin E, and 0.4-0.6 g of vitamin C. In this embodiment, the antioxidant includes 1 g of sodium L ascorbate, 0.5 g of vitamin E, and 0.5 g of vitamin C.

[0053] The prepared buffer and freezing solution were filtered through a sterile filter using a 0.22 um filter membrane to ensure that there was no microbial contamination.

[0054] Further, in this embodiment, the amino acid mixture includes 1-2 parts of L-alanine, 2-4 parts of L-alanine-L-glutamine, 3-5 parts of L-isoleucine, 1-6 parts of L-methionine, 3-6 parts of L-phenylalanine, 4-8 parts of L-proline, 5-7 parts of L-serine, 9-10 parts of L-threonine and 5-8 parts of L-tryptophan.

[0055] Specifically: the amino acid mixture includes 1.5g L-alanine, 3g L-alanine-L-glutamine, 4g L-isoleucine, 2g L-methionine, 4g L-phenylalanine, 6g L-proline, 6g L-serine, 8g L-threonine and 7g L-tryptophan. After mixing, 10g is weighed.

[0056] The cryoprotectant contains 90-110 ml of propylene glycol, 0.8-1.2 g of sucrose and 0.8-1.2 g of trehalose. In this embodiment, the cryoprotectant contains 100 ml of propylene glycol, 1 g of sucrose and 1 g of trehalose.

[0057] Further, in this embodiment, the serum substitute includes 2-3 parts of D-biotin, 2-5 parts of choline chloride, 5-6 parts of folic acid, 3-6 parts of inositol, 2-4 parts of nicotinamide, 5-6 parts of D-calcium pantothenate, 1-2 parts of pyridoxal hydrochloride, 1-3 parts of pyridoxine hydrochloride, 1-2 parts of riboflavin, 2-3 parts of ammonium sulfate hydrochloride and 1-2 parts of hypoxanthine.

[0058] Specifically: D-biotin 2.5g, choline chloride 3g, folic acid 5g, inositol 5g, niacinamide 3g, D-calcium pantothenate 5g, pyridoxal hydrochloride 1.2g, pyridoxine hydrochloride 2g, riboflavin 1.5g, ammonium sulfate hydrochloride 2.5g and hypoxanthine 1.5g.

[0059] A freezing solution is prepared by the above-mentioned method for preparing the freezing solution for tissues.

[0060] In order to facilitate those skilled in the art to further understand the present invention, the present invention is further described below in conjunction with specific test methods.

[0061] The mouse back skin was depilated and cleaned, and a 1 cm*1 cm area with a thickness of about 1 mm to 2 mm was taken, and rinsed with sterile saline, and placed in a 5 ml cryopreservation tube. 4 ml of this cryopreservation solution and other 4 cryopreservation solutions were added to the cryopreservation tube. The four cryopreservation solutions are as follows:

[0062] Brand 1 purchased Wako cryopreservation medium - serum-free cell cryopreservation medium, product number: 302-14686;

[0063] Brand 2 purchased Yazyme cryopreservation solution, item number BY002;

[0064] Brand 3 purchased Xiaopeng cryopreservation solution, item number C3520-0100;

[0065] Brand 4: Aesthesia cryopreservation solution, item number AC-1001049;

[0066] Three replicate samples were set up for each freezing solution.

[0067] In actual use, there is no need for programmed cooling, and the samples are directly frozen at -80 degrees Celsius, and then placed in liquid nitrogen overnight. After 10 days, the cell activity of the skin tissue in different cryopreservation solutions was observed and compared.

[0068] Since phosphatidylserine is only distributed on the inner side of the lipid bilayer of the cell membrane in normal cells, in the earliest stage of cell apoptosis, the membrane phosphatidylserine flips from the inner side of the lipid membrane to the outer side. Annexin V is a calcium-dependent phospholipid binding protein with a high affinity for phosphatidylserine, so it can bind to the cell membrane of early apoptotic cells through the phosphatidylserine exposed on the outer side of the cell. Therefore, Annexin V is used as one of the sensitive indicators for detecting early cell apoptosis.

[0069] Propidium iodide (PI) is a nucleic acid dye that cannot penetrate intact cell membranes. However, due to the increased cell membrane permeability of cells in the middle and late stages of apoptosis and dead cells, PI can penetrate the cell membrane and stain the cell nucleus red. Therefore, by matching Annexin V with PI, cells in different stages of apoptosis can be distinguished: PI is excluded from living cells (Annexin V- / PI-) and early apoptotic cells (Annexin V+ / PI-), while late apoptotic cells and necrotic cells are stained with both Annexin V and PI to show double positive (Annexin V+ / PI+).

[0070] The specific detection steps are as follows:

[0071] Thaw the cryotube in a 37°C water bath for 25 min. Rinse the tissue in a 60 mm glass dish containing 2 mL of pre-cooled PBS, cut it into small pieces with ophthalmic scissors, grind the tissue gently with a grinder, collect the cell suspension, filter it with a 200-mesh cell sieve, centrifuge it at 300 g for 5 min, discard the supernatant, wash it twice with PBS, centrifuge it at 300 g for 5 min, discard the supernatant, and collect the cell pellet by centrifugation for later use.

[0072] The cell suspension sample was centrifuged at 250 g for 5 min, the supernatant was discarded, and the sample was washed twice with PBS and centrifuged at 250 g for 5 min. The supernatant was discarded to obtain a cell pellet.

[0073] After resuspending the cells with 500 μL Binding Buffer, add 5 μL Annexin V and gently blow evenly, then add 5 μL PI and mix well; incubate at room temperature in the dark for 10 minutes, and analyze on the machine.

[0074] Specific test results such as Figure 1-Figure 6 As shown, according to the comparison of the test results, the effect of freezing for 10 days under the cryopreservation solution of the present invention is the best, and the survival rate is closest to that of fresh tissue cells, which shows that the cryopreservation solution has low cytotoxicity, high safety and strong effectiveness.

[0075] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.

[0076] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. It should be pointed out that any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for preparing a freezing solution for tissues, characterized in that: Cryopreservation solutions include culture medium, buffer, cryoprotectant, antioxidant, serum replacement and antibiotics; Wherein, the culture medium comprises glucose and an amino acid mixture; Buffers include sodium chloride, potassium chloride, disodium hydrogen phosphate anhydrous, sodium dihydrogen phosphate monohydrate, zinc sulfate heptahydrate, sodium bicarbonate, and sodium hydroxide; Cryoprotectants include propylene glycol, sucrose, and trehalose; Serum substitutes include D-biotin, choline chloride, folic acid, inositol, niacinamide, D-calcium pantothenate, pyridoxal hydrochloride, pyridoxine hydrochloride, riboflavin, ammonium sulfate hydrochloride, and hypoxanthine; Antibiotics include gentamicin; The specific preparation method is as follows: Step 1, buffer preparation: Put 6-9g of sodium chloride, equal weights of potassium chloride, anhydrous disodium hydrogen phosphate, monohydrated sodium dihydrogen phosphate, heptahydrated zinc sulfate, sodium bicarbonate and sodium hydroxide (totaling 2-4g) into a clean beaker, add about 700-800ml of distilled water into the container, stir to completely dissolve the solid, adjust the pH to 7.0-7.4 with sodium hydroxide, continue to add distilled water until the total volume reaches 1L, stir again to make a buffer solution for use; Step 2, preparation of cryopreservation solution: Mix 25-35g of glucose, 8-12g of amino acid mixture, 1.7-2.3g of antioxidant, 4-6g of serum substitute, and 0.8-1.2g of gentamicin evenly into a clean beaker, add buffer to 800-900ml, and stir evenly, then add cryoprotectant and continue stirring evenly; The prepared buffer and freezing solution were filtered through a sterile filter using a 0.22 um filter membrane to ensure that there was no microbial contamination.

2. A method for preparing a freezing solution for tissue according to claim 1, characterized in that: The amino acid mixture includes 1-2 parts of L-alanine, 2-4 parts of L-alanine-L-glutamine, 3-5 parts of L-isoleucine, 1-6 parts of L-methionine, 3-6 parts of L-phenylalanine, 4-8 parts of L-proline, 5-7 parts of L-serine, 9-10 parts of L-threonine and 5-8 parts of L-tryptophan.

3. A method for preparing a freezing solution for tissue according to claim 2, characterized in that: The amino acid mixture includes 1.5 parts of L-alanine, 3 parts of L-alanine-L-glutamine, 4 parts of L-isoleucine, 3 parts of L-methionine, 4 parts of L-phenylalanine, 6 parts of L-proline, 6 parts of L-serine, 9 parts of L-threonine and 3 parts of L-tryptophan.

4. The method for preparing a freezing solution for tissue according to claim 1, characterized in that: Antioxidants include 0.9-1.1g of sodium L-ascorbate, 0.4-0.6g of vitamin E, and 0.4-0.6g of vitamin C.

5. A method for preparing a freezing solution for tissue according to claim 4, characterized in that: Antioxidants include 1g of sodium L-ascorbate, 0.5g of vitamin E, and 0.5g of vitamin C.

6. The method for preparing a freezing solution for tissue according to claim 1, characterized in that: The cryoprotectant contains 90-110 ml of propylene glycol, 0.8-1.2 g of sucrose and 0.8-1.2 g of trehalose.

7. A method for preparing a freezing solution for tissue according to claim 6, characterized in that: The cryoprotectant contains 100 ml of propylene glycol, 1 g of sucrose and 1 g of trehalose.

8. The method for preparing a freezing solution for tissue according to claim 1, characterized in that: The serum substitute includes 2-3 parts of D-biotin, 2-5 parts of choline chloride, 5-6 parts of folic acid, 3-6 parts of inositol, 2-4 parts of nicotinamide, 5-6 parts of D-calcium pantothenate, 1-2 parts of pyridoxal hydrochloride, 1-3 parts of pyridoxine hydrochloride, 1-2 parts of riboflavin, 2-3 parts of ammonium sulfate hydrochloride and 1-2 parts of hypoxanthine.

9. A freezing solution, characterized in that: The cryopreservation solution is prepared by the method for preparing a tissue cryopreservation solution according to any one of claims 1 to 8.